204 related articles for article (PubMed ID: 34304374)
1. Olanzapine/Samidorphan: First Approval.
Paik J
Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
[TBL] [Abstract][Full Text] [Related]
2. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
[TBL] [Abstract][Full Text] [Related]
3. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
Faden J; Serdenes R; Citrome L
Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
Corrao MM; Nelson LA
CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine/samidorphan (Lybalvi) for schizophrenia and bipolar disorder.
Med Lett Drugs Ther; 2021 Nov; 63(1638):191-192. PubMed ID: 35085217
[No Abstract] [Full Text] [Related]
7. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
Monahan C; McCoy L; Powell J; Gums JG
Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357
[TBL] [Abstract][Full Text] [Related]
8. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
Gao J; Li J; Lu X; Yang J
Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507
[TBL] [Abstract][Full Text] [Related]
9. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M
J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
Sun L; McDonnell D; von Moltke L
Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
[TBL] [Abstract][Full Text] [Related]
11. Treating Schizophrenia and Bipolar I Disorder in the Real-World Setting: Effectiveness and Safety of Olanzapine/Samidorphan Combination.
Price MZ; Price RL
Prim Care Companion CNS Disord; 2024 Apr; 26(2):. PubMed ID: 38579267
[No Abstract] [Full Text] [Related]
12. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
Sun L; Mills R; Sadler BM; Rege B
J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
[TBL] [Abstract][Full Text] [Related]
13. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
14. Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma.
Salem H; Samir E; Mazen DZ; Madian H; Elkhateeb AE; Elaraby M; Rasekh MI; Gamal A
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jun; 274():121105. PubMed ID: 35272122
[TBL] [Abstract][Full Text] [Related]
15. Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan.
Chambers A; Patton J; Wills BK
Am J Emerg Med; 2024 May; 79():230.e1-230.e2. PubMed ID: 38556414
[TBL] [Abstract][Full Text] [Related]
16. How Much of an Advance Is the Addition of Samidorphan to Olanzapine?
Buchanan RW
Am J Psychiatry; 2020 Dec; 177(12):1113-1114. PubMed ID: 33256454
[No Abstract] [Full Text] [Related]
17. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.
Yagoda S; Graham C; Simmons A; Arevalo C; Jiang Y; McDonnell D
CNS Spectr; 2021 Aug; 26(4):383-392. PubMed ID: 32393412
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N
Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206
[TBL] [Abstract][Full Text] [Related]
20. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Sun L; Yagoda S; Yao B; Graham C; von Moltke L
Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
